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ORIGINAL ARTICLE68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary
Prostate CancerChristos Sachpekidis, MD,*† Klaus Kopka, PhD,‡ Matthias Eder, PhD,‡
Boris A. Hadaschik, MD,§ Martin T. Freitag, MD,|| Leyun Pan, PhD,*
Uwe Haberkorn, MD,*¶ and Antonia Dimitrakopoulou-Strauss, MD*Purpose: The aim of our study is to assess the pharmacokinetics and
biodistribution of 68Ga-PSMA-11 in patients suffering from primary pros-
tate cancer (PC) by means of dynamic and whole-body PET/CT.
Materials and methods: Twenty-four patients with primary, previously un-
treated PC were enrolled in the study. All patients underwent dynamic PET/
CT (dPET/CT) scanning of the pelvis and whole-body PET/CT studies
with 68Ga-PSMA-11. The evaluation of dPET/CT studies was based on
qualitative evaluation, SUV calculation, and quantitative analysis based
on two-tissue compartment modeling and a noncompartmental approach
leading to the extraction of fractal dimension (FD).
Results:A total of 23/24 patients (95.8%) were 68Ga-PSMA-11 positive. In
9/24 patients (37.5%), metastatic lesions were detected. PC-associated
lesions demonstrated the following mean values: SUVaverage = 14.3,
SUVmax = 23.4, K1 = 0.24 (1/min), k3 = 0.34 (1/min), influx = 0.15 (1/
min), and FD = 1.27. The parameters SUVaverage, SUVmax, k3, influx,
and FD derived from PC-associated lesions were significantly higher than
respective values derived from reference prostate tissue. Time-activity curves
derived from PC-associated lesions revealed an increasing 68Ga-PSMA-11
accumulation during dynamic PETacquisition. Correlation analysis revealed
a moderate but significant correlation between PSA levels and SUVaverage
(r = 0.60) and SUVmax (r = 0.57), and a weak but significant correlation be-
tween Gleason score and SUVaverage (r = 0.33) and SUVmax (r = 0.28).
Conclusion: 68Ga-PSMA-11 PET/CT confirmed its capacity in detecting
primary PC with a detection rate of 95.8%. Dynamic PET/CT studies of
the pelvis revealed an increase in tracer uptake in PC-associated lesions dur-
ing the 60 minutes of dynamic PETacquisition, a finding with potential ap-
plications in anti-PSMA approaches.
Key Words: 68Ga-PSMA-11 PET/CT, primary prostate cancer,
two-tissue compartment model
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T o date, the contribution of conventional imaging modalities instaging and management of men with prostate cancer (PC) is
smaller than in other common cancers.1–6 Imaging studies exhibit
a low positivity in clinically localized disease (with the exception
of patients with PSA levels ≥20 ng/mL or Gleason scores ≥8)
and a low sensitivity in detecting lymph node metastases. WithReceived for publication April 19, 2016; revision accepted July 3, 2016.
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Copyright © 2016 Wolters Kluwer Hthe exception of 18F-choline and 11C-acetate PET/CT, which
demonstrated a high sensitivity in the biochemical relapse of
PC,7–9 the performance of most imaging approaches in detecting
metastatic or recurrent PC in the setting of biochemical relapse is
also not high.4,10–14 Therefore, the development and introduction
into clinical practice of new imaging modalities that carry high sen-
sitivity and specificity in PC detection is of outmost importance.
The first results of the novel agent 68Ga-labeledGlu-urea-Lys-
(Ahx)-HBED-CC (68Ga-PSMA-11) have been very satisfying, ren-
dering the addition of 68Ga-PSMA-11 PET/CT to the diagnostic
armamentarium a very promising approach in PC staging.10,15–17
This tracer carries some very desirable characteristics for the imaging
approach of PC: specific targeting of prostate-specific membrane
antigen (PSMA), fast blood clearance, low background activity,
and a relative short physical half-life of the isotope (68.3 min).18,19
Dynamic PET/CT (dPET/CT) is a modality that allows regis-
tration of pharmacokinetic information over time, unlike classical
whole-body PET/CT protocols that enable the acquisition of patient
images only at one time point after tracer injection. Compartment
analysis provides the possibility to assess dedicated aspects of tracer
kinetics, which are associated with molecular biological data, and
represents simplifications of actual complicated in vivo processes.
In this sense, the two-tissue compartment model performed in the
present study is an approximation of the underlying biological sys-
tem regarding 68Ga-PSMA-11 metabolism. The application of two-
tissue compartment modeling in the 68Ga-PSMA-11 dynamic PET
data leads to the extraction of four transport rates (K1, k2, k3, k4),
which describe the tracer exchange between plasma and tissue. In
particular, K1 and k2 reflect the forward and reverse transport of
the radiotracer between plasma and the reversible compartment,
which involves free tracer in interstitial fluid. Respectively, k3 and
k4 account for forward and reverse transport between the reversible
and trapped compartment, which involves the PSMA-specific part
of tracer metabolism, leading to the assumption that the constant
rate k3 is associated with tracer binding on the receptor (PSMA)
and its internalization, and k4 with dissociation of the tracer from
the receptor and externalization.20,21 This model has been used by
our group for the pharmacokinetic analysis of 68Ga-PSMA-11 stud-
ies in patients with biochemical relapse of PC.20
The aim of this study is to evaluate the biodistribution and
pharmacokinetics of 68Ga-PSMA-11 in patients with primary PC by
means of dynamic and whole-body PET/CT. The correlation between
PSA levels and 68Ga-PSMA-11 PET parameters is also investigated.
PATIENTS AND METHODS
Patients
Twenty-four patients suffering from primary, previously un-
treated PC were enrolled in the study. Their median age was 69 years
(range = 43–84 years). The median PSA value was 24.1 ng/mL
(range = 3.2–200.0 ng/mL). Gleason score was available in 21/24 pa-
tients (median = 7; range = 7–9). Table 1 presents analytically the char-
acteristics of the patients investigated. The analysis was conducted in
accordance to the Declaration of Helsinki with institutional approval.016 www.nuclearmed.com e473
ealth, Inc. All rights reserved.
TABLE 1. Characteristics of the Patients Investigated in the Study
Patient No.
Age
(y)
Dosage
(MBq)
PSA
(ng/mL)
Gleason
Score
PC foci in
the Prostate
Lymph
Node
Metastases
Bone
Metastases
Soft
Tissue
Metastases
1 72 245 3.4 7 (3 + 4) 1
2 74 352 30.0 n.a. 1
3 73 338 80.0 n.a. 1 Innumerable lesions 1
4 57 120 40.0 7 (3 + 4) Multifocal uptake 4
5 69 268 13.0 7 (4 + 3) 1 1 2
6 76 134 54.0 7 (4 + 3) Multifocal uptake 8
7 71 294 50.1 7 (3 + 4) 1
8 57 268 3.2 9 2 (multifocal uptake)
9 58 182 76.0 8 1 1 5
10 72 283 13.7 9 No uptake
11 75 288 200.0 7 (3 + 4) 1 26 8 1
12 60 123 15.2 9 Multifocal uptake
13 66 304 27.0 8 1 2
14 71 272 9.1 9 1 1
15 66 285 25.3 7 (3 + 4) 1 2
16 58 192 5.8 7 (4 + 3) 1
17 69 323 37.0 7 (3 + 4) 1
18 66 69 11.4 7 (3 + 4) 2 (multifocal uptake)
19 65 268 7.8 9 2 (multifocal uptake)
20 43 212 23.0 n.a. 1
21 73 232 6.3 7 (3 + 4) 2 (multifocal uptake)
22 84 338 16.4 9 3 (multifocal uptake)
23 70 246 27.6 8 1
24 74 351 12.3 9 1
n.a. indicates not available.
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The patients were intravenously administered with 68Ga-
PSMA-11, the 68Ga-labeled HBED-CC conjugate of the PSMA-
specific pharmacophore Glu-NH-CO-NH-Lys(Ahx), which
was synthesized and radiolabeled as published previously
(range = 69–352 MBq, median = 268 MBq).22–24
Data acquisition consisted of two parts: the dynamic part
(dPET/CT studies) and the static part (whole-body PET/CT).
dPET/CT studies were performed over the pelvic area and the lower
abdomen (two bed positions, 44 cm) for 60 minutes using a 24-
frame protocol (10 frames of 30 s, 5 frames of 60 s, 5 frames of
120 s, and 8 frames of 300 s). Whole-body static imaging was per-
formed in all patients with an image duration of 2 minutes per bed
position for the emission scans after the end of the dynamic acqui-
sition. A dedicated PET/CT system (BiographmCT, 128S; Siemens
Co., Erlangen, Germany) with an axial field of viewof 21.6 cmwith
TruePoint and TrueV, operated in a three-dimensional mode, was
used. A low-dose attenuation CT (120 kV, 30 mA) was used for
the attenuation correction of the dynamic emission PET data and
for image fusion. A second low-dose CT from the skull to the knees
(120 kV, 30 mA) was performed after the end of the dynamic series.
All PET images were attenuation-corrected and an image matrix of
400  400 pixels was used for iterative image reconstruction. Iter-
ative image reconstruction was based on the ordered subset expec-
tation maximization algorithm (OSEM) with 6 iterations and 12
subsets. The reconstructed images were converted to SUV images
based on the formula25: SUV = tissue concentration (Bq/g)/
(injected dose (Bq)/body weight (g)). The SUVs 55 to 60 minutes
post-injection were used for quantification of tracer data.e474 www.nuclearmed.com
Copyright © 2016 Wolters Kluwer HData Analysis
Data analysis and evaluation was based on visual analysis of
the PET/CT scans, semiquantitative evaluation based on SUV calcu-
lations, and quantitative analysis. Qualitative analysis was based on
visual assessment of the PET/CT scans. Two nuclear medicine physi-
cians (CS, ADS) evaluated the tracer accumulating areas on
transaxial, coronal, and sagittal images. In particular, areas presenting
with significantly enhanced 68Ga-PSMA-11 uptake, apart from those
in which an increased tracer uptake is considered physiological, were
considered indicative for PC involvement. PC-associated lesionswere
classified in the following categories: primary tumors (PC), lymph
node metastases, bone metastases, and soft tissue metastases.
Semiquantitative evaluation was based onvolumes of interest
(VOIs) and on subsequent calculation of SUV. VOIs were drawn
with an isocontour mode (pseudo-snake) and were placed over the
PC-associated lesions, and over regions of the prostate gland that
showed no pathological tracer accumulation and, thus, served as refer-
ence.26 SUVswere calculated in themajority of lesions. All SUVswere
assessed during the whole-body/static acquisition, 80 to 90 minutes
p.i. However, pelvic lesions‘ SUVs were calculated at two time
points, at the end of the dynamic PET acquisition (55–60 min p.i.)
and during the whole-body/static acquisition (80–90 min p.i.), to as-
sess changes in tracer uptake at different time points. Lesions that
were <2mmorwithout clearly delineatedmarginswere not evaluated.
The quantitative evaluation of the dynamic PET datawas per-
formed with PMOD software (PMOD Technologies Ltd., Zürich,
Switzerland). It was based on irregular VOIs, drawn with an
isocontour mode (pseudo-snake), placed over PC-associated le-
sions.26 Time-activity curves (TACs) were created using VOIs.© 2016 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
Clinical Nuclear Medicine • Volume 41, Number 11, November 2016 68Ga-PSMA-11 PET/CT in Prostate CancerOnly lesions located in the anatomic area of the pelvis, where dPET/
CTwas performed, were evaluated quantitatively. A detailed quanti-
tative evaluation of tracer kinetics was performed based on two-
tissue compartment modeling.27,28 The accurate measurement of
the input function requires arterial blood sampling. However, it
can be retrieved simplified and noninvasively from the image data
with good accuracy according to methods already reported in liter-
ature and performed previously from our group.29,30 For this reason,
at least seven consecutive ROIs were placed over the common iliac
artery to obtain the blood data for 68Ga-PSMA-11. The recovery
coefficient was 0.85 for a diameter of 8 mm. The application of
two-tissue compartment modeling leads to the extraction of the pa-
rameters K1, k2, k3, and k4. In this study, the constants K1, k2, k3,
and k4 were calculated taking into account the vascular fraction
(VB) in a VOI as an additional variable. Themodel parameters were
accepted when K1, k2, k3, and k4 were <1 and VB >0. The unit for
the rate constants K1, k2, k3, and k4 is 1/min, whereas VB is associ-
ated with the volume of blood exchanging with tissue. After com-
partmental analysis, we calculated the global influx (Ki) from the
compartment data using the formula: Ki = (K1  k3)/(k2 + k3). In
addition to creating VOIs over foci indicative of malignant involve-
ment, we also created VOIs over normal prostate tissue (referenceFIGURE 1. 68Ga-PSMA-11 PET/CT of a 66-year-old PC patient wi
projection (MIP) (A) reveals the primary tumor (arrow) and two sk
(arrows). Normal biodistribution of the tracer in lacrimal glands, s
and bladder. Transaxial PET/CT at the pelvic level (B) shows the p
PET/CT at the thoracic level (C) shows the osseous metastasis in t
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2016 Wolters Kluwer Htissue). The values extracted from reference tissue were then com-
pared to the respective values of PC involvement.
Apart from compartmental analysis, a noncompartment
model was used to calculate the fractal dimension (FD). FD is a pa-
rameter of heterogeneity based on chaos theory. The values of FD
vary from 0 to 2 showing the deterministic or chaotic biodistribution
of the 68Ga-PSMA-11 activity over time.31
Data were statistically evaluated using the STATA/SE 12.1
(StataCorp) software on an Intel Core (2·3.06 GHz, 4GBRAM) run-
ning with Mac OS X 10.8.4 (Apple Inc., Cupertino, CA). The statis-
tical evaluation was performed using descriptive statistics, box plots,
Wilcoxon rank-sum test, and Spearman rank correlation analysis. The
results were considered significant for P less than 0.05 (P < 0.05).
RESULTS
Whole-Body PET/CT Studies
Visual Evaluation
In 23/24 patients, at least one PC-associated lesion was de-
tected, leading to a detection rate of 95.8% (Figs. 1 and 2). Nor-
mal radiotracer biodistribution was demonstrated in the lacrimalth a PSA of 27 ng/mL. Whole-body maximum intensity
eletal metastases in the 9th thoracic vertebra and 7th left rib
alivary glands, nasal mucosa, liver, spleen, bowel, kidneys,
rimary tumor in the left prostate lobe (arrow). Transaxial
he 9th thoracic vertebra (arrow).
www.nuclearmed.com e475
ealth, Inc. All rights reserved.
FIGURE 2. 68Ga-PSMA-11 PET/CT of a 75-year-old PC patient. Whole-body maximum intensity projection (MIP) (A) reveals the
primary tumor, and multiple lymph node and skeletal metastases. Transaxial PET/CT at the lumbar spine level (B) shows three
retroperitoneal metastases. Transaxial PET/CT at the level of os sacrum (C) shows multiple iliacal lymph node metastases and
infiltration of the os sacrum.
Sachpekidis et al Clinical Nuclear Medicine • Volume 41, Number 11, November 2016glands, salivary glands, nasal mucosa, liver, spleen, bowel, kidneys,
and bladder. One patient demonstrated tracer uptake neither in
PC-associated lesions nor in tissues, where physiological uptake
is expected. Eight patients demonstrated multifocal tracer uptake
in the prostate gland, in three of which the precise number of
PC lesions could not be calculated. In one patient, the extent of
lymph node and bone metastatic involvement was very large,
rendering the exact calculation of metastatic osseous and lymph
node metastases practically impossible. Metastatic disease was
detected in nine patients, and five of them had already been ex-
amined with conventional imaging modalities (CT and/or MRI)
before the 68Ga-PSMA-11 PET/CT. Four of these five pre-
examined subjects were positive for metastases based on conven-
tional imaging, whereas one was negative. Interestingly, in this
subgroup of 5 patients, only 4 of the total 19 68Ga-PSMA-11-
positive metastatic lesions were depicted in the conventional mo-
dalities. A total of 88 PC-associated lesions were evaluated. In
particular, 26 lesions corresponded to primary prostatic tumors,
34 to lymph node metastases, 26 to bone metastases, and 2 to soft
tissue metastases (Table 1).FIGURE 3. Box plots of SUVs derived from primary PC lesions
(left row), lymph node metastases (middle row), and
osseous metastases (right row). No statistically significant
differences are depicted between different sites of PC
involvement (P < 0.05). SUV has no unit.Semiquantitative Evaluation
A total of 72 of the 88 lesions were semiquantitatively
(SUV) evaluated. In particular, SUVs were calculated for 26 pri-
mary prostatic tumors, 16 lymph node metastases, and 30 bone
metastases (Fig. 3). According to Wilcoxon rank-sum test, le-
sions’ SUVs were significantly higher than respective values
derived from reference prostate gland. Spearman rank correla-
tion analysis showed that PSA levels correlated significantlye476 www.nuclearmed.com
Copyright © 2016 Wolters Kluwer Hwith PC-associated lesions’ SUVaverage (r = 0.60, P < 0.0001)
and SUVmax (r = 0.57, P < 0.0001). Moreover, a weak but signif-
icant correlation was demonstrated between Gleason score and
SUVaverage (r = 0.33, P < 0.05) and SUVmax (r = 0.28, P < 0.05).© 2016 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
FIGURE 4. Box plots of parameters K1, k3, and influx derived
from primary PC lesions (left row), lymph node metastases
(middle row), and osseous metastases (right row). k3 from
osseous metastases is significantly higher than k3 from
lymph node metastases (P < 0.05). Otherwise, no other
statistically significant differences are depicted between
sites of PC involvement regarding these parameters. The
values of parameters K1, k3, and influx are 1/min.
Clinical Nuclear Medicine • Volume 41, Number 11, November 2016 68Ga-PSMA-11 PET/CT in Prostate CancerDynamic PET/CT Studies of the Pelvis
Fifty-eight 68Ga-PSMA-11 pelvic lesions were quantitatively
evaluated by means of dPET/CT (26 primary tumors, 13 lymph
node metastases, and 19 osseous metastases). The values of SUVs
and kinetic parameters derived from PC-associated lesions and from
reference prostate gland are depicted in Table 2. Wilcoxon rank-
sum revealed that, besides SUVaverage and SUVmax, the parameters
k3, influx, VB, and FD were significantly higher in PC-related le-
sions than in reference tissue. Regarding the different PC recurrence
sites, Wilcoxon rank-sum test revealed that osseous metastatic le-
sions had higher FD values than primary tumors and lymph node
metastases. Furthermore, k3 from osseous lesions was higher than
k3 from lymph node metastases (P < 0.05) (Fig. 4). No significant
correlations were observed between kinetic parameters and PSA
or Gleason score.
Moreover, we calculated the SUVs of the pelvic lesions at
two time points: at the end of the dynamic PET acquisition
(55–60 min p.i.; “early” SUVs) and during the whole-body/static
acquisition (80–90 min p.i.; “late” SUVs). This evaluation revealed
that both SUVaverage and SUVmax increased at late acquisition times.
In particular, the mean value of “early” SUVaverage was 14.9 (me-
dian = 12.4), whereas the mean value of “late” SUVaverage was 17.8
(median = 15.8). Respectively, the mean value of “early” SUVmax
was 24.4 (median = 19.6), whereas the mean value of “late” SUVmax
was 29.0 (median = 24.5).
Dynamic PET/CT scanning led also to the extraction of
time-activity curves (TACs), which show the activity concentration
of 68Ga-PSMA-11 in the selected VOI during the 60 minutes of
dPET/CT acquisition. Figure 5 demonstrates the resulting TACs
derived from a primary tumor, an osseous metastasis, a lymph node
metastasis, and reference prostate tissue. The curves show that
68Ga-PSMA-11 concentration increases in the PC-associated le-
sions in comparison to normal prostate.TABLE 2. Descriptive Statistics of 68Ga-PSMA-11 SUVs and
Kinetic Parameters
Parameters Mean Median Minimum Maximum
PC lesions SUVaverage* 14.3 11.8 2.5 49.8
SUVmax* 23.4 19.1 3.3 74.1
K1 (1/min) 0.24 0.17 0.03 0.89
k2 (1/min) 0.21 0.14 6.8e–100 0.99
k3* (1/min) 0.34 0.28 0.01 0.99
k4 (1/min) 0.05 0.02 5.87e–99 0.91
Influx* (1/min) 0.15 0.09 0.02 0.77
VB* 0.02 0.005 8.99e–08 0.17
FD* 1.27 1.31 1.06 1.36
Reference SUVaverage 1.6 1.5 0.23 3.0
SUVmax 2.2 2.4 0.6 4.0
K1 (1/min) 0.15 0.12 0.04 0.27
k2 (1/min) 0.28 0.22 0.06 0.56
k3 (1/min) 0.11 0.12 0.04 0.18
k4* (1/min) 0.1 0.07 0.4 0.32
Influx (1/min) 0.04 0.05 0.1 0.06
VB 0.02 0.002 0.0001 0.1
FD 1.02 1.06 0.06 1.15
The SUVs are derived from the 72 lesions, which were evaluated. The kinetic
parameters are derived after application of two-tissue compartment modeling in the
-dPET/CT data from the pelvis (58 lesions). The values of parameters K1, k2, k3, k4,
and influx are 1/min. SUV, VB, and FD have no unit.
*Significant probabilities (P < 0.05).
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2016 Wolters Kluwer HSpearman rank correlation analysis was performed between
68Ga-PSMA-11 quantitative parameters. The strongest correlations
(P < 0.05) were found between FD and SUVaverage (r = 0.93),
FD and SUVmax (r = 0.87), FD and influx (r = 0.77), and between
influx and SUVaverage (r = 0.76), influx and SUVmax (r = 0.75),
and influx and K1 (r = 0.82) (Table 3).DISCUSSION
The first satisfying results from the introduction of 68Ga-
PSMA-11 in PC diagnostics have rendered PET imaging with this
novel agent highly promising.15–17 In this analysis, we studied the
detection rate and pharmacokinetics of 68Ga-PSMA-11 in a group
of patients suffering from primary, histologically confirmed PC,
by means of dynamic and whole-body PET/CT.
Regarding whole-body PET/CT studies, all patients but one
were 68Ga-PSMA-11 positive (95.8%). This high detection rate is
of no surprise because the radioligand, which specifically binds to
the prostate-specific membrane antigen (PSMA), is expressed prac-
tically in all PCs.3,32,33
Correlation analysis revealed that PSA plasma levels corre-
lated positively with tracer uptake in PC-associated lesions, as
reflected by SUVaverage (r = 0.60) and SUVmax (r = 0.57), a result
in agreement with previous results from our group in patients with
biochemical recurrence of PC.20 Furthermore, 68Ga-PSMA-11 up-
take, measured by SUVaverage and SUVmax, correlated weak but sig-
nificantly with Gleason score. This result is in line with the findings
of Rowe et al., who also demonstrated a significant, positive corre-
lation between Gleason score and SUVmax of the radiotracer
18F-DCFBC that also targets PSMA in a group of 13 patients with
primary PC.34 A potential explanation for theseweak/moderate cor-
relations between 68Ga-PSMA-11 uptake and the previously men-
tioned parameters could be the heterogeneity of PSMA expression
in PC, also in correlation with PSA levels and Gleason score, which
has been highlighted in some studies.35,36
Dynamic PET/CT imaging revealed that PC-associated le-
sions demonstrate higher 68Ga-PSMA-11 uptake (SUVs), higherwww.nuclearmed.com e477
ealth, Inc. All rights reserved.
FIGURE 5. Representative time-activity curves (TACs) derived
after application of two-tissue compartment modeling in the
dynamic PET/CT data. The TACs are derived from VOIs drawn
over a primary PC (first row), an osseous metastasis (second
row), a lymphnodemetastasis (third row), and reference prostate
gland (fourth row). The curves derived from PC-associated
lesions showthat 68Ga-PSMA-11accumulates increasingly in the
respectiveVOIs in the60minutes of dynamic PET acquisition.
On the other hand, the TAC derived fromnormal prostate tissue
demonstrates a loweraccumulationof 68Ga-PSMA-11during
dynamic PET acquisition. The values of parameters K1, k3, and
influx are 1/min. SUV and FD have no unit.
TABLE 3. Results of the Spearman Rank Correlation
Analysis Between PC-Associated Lesions’ Quantitative and
Semiquantitative (SUVs) Parameters of 68Ga-PSMA-11,
Derived from dPET/CT of the Pelvis (58 Evaluated Lesions)
SUVaverage SUVmax
K1
(1/min)
k3
(1/min)
Influx
(1/min)
SUVaverage
SUVmax 0.9290*
K1 (1/min) 0.4538* 0.4757*
k3 (1/min) 0.6532* 0.5676* 0.010
Influx (1/min) 0.7598* 0.7519* 0.8212* 0.3177*
FD 0.9287* 0.8736* 0.4752* 0.5958* 0.7711*
The values of parameters K1, k3, and influx are 1/min. SUVand FD have no unit.
Values were considered significant for P < 0.05.
*Significant probabilities (P < 0.05).
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versible and trapped compartment, which is associated with higher
receptor binding and internalization according to our hypothesis
(k3), and higher influx than reference prostate gland. The fact that
malignant lesions demonstrate higher kinetic values than reference
tissue or benign lesions has been highlighted for various tumors
with different tracers.30,37–40
The lesions’ TACs showed a steadily increasing tracer accu-
mulation during the 60minutes of dynamic PETacquisition (Fig. 5).
Furthermore, the comparison of SUVs in the last frame of dynamic
acquisition (55–60 min p.i.) and in the static/whole-body late im-
ages (80–90min p.i.) revealed an increase of tracer uptake at late ac-
quisition times, which has been described in a previous study even
for longer time intervals.41 The finding that 68Ga-PSMA-11 shows
a high receptor binding and internalization, and accumulates in-
creasingly in the primary PC-associated lesions is in good agree-
ment with preclinical data of the tracer24 and previously published
data from our group regarding the behavior of 68Ga-PSMA-11 in
pre-treated PC patients with biochemical recurrence.20 The here
presented findings confirm the previous results also in patients suf-
fering from primary PC and imply a potential efficacy of anti-
PSMA approaches in primary PC-associated lesions, especially
considering the promising results of the radioligand-based anti-
PSMA therapy with 177Lu-PSMA-61742 and 131I-MIP-1095.43
This study has some limitations. Firstly, the number of patients
enrolled is small. Secondly, most but not all of the 68Ga-PSMA-11-
positive findings on PET/CT were histopathologically confirmed.
Nevertheless, the so far collected data regarding the 68Ga-PSMA
ligand imply that tracer-avid PET lesions with morphological cor-
relation have to be considered as positive for PC involvement.44 Fi-
nally, an expansion of the dynamic PET acquisition at later time
points (for example at 2 h or 3 h p.i.) would provide more robust
data regarding 68Ga-PSMA-11 accumulation in PC-associated re-
gions over time, a limitation partially compensated by calculating
SUVs of pelvic lesions at the end of dynamic PET acquisition
and during the static studies.CONCLUSION
In the present study, the diagnostic efficacy of 68Ga-PSMA-
11 PET/CT in primary PC was confirmed with an overall detection
rate of 95.8%. A positive correlation was demonstrated between
SUVs of 68Ga-PSMA-11-positive lesions and PSA plasma levels,
and Gleason score. Dynamic PET/CT studies of the pelvis demon-
strated that tracer uptake in PC-associated lesions is increasing© 2016 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
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two-tissue compartment modeling revealed a high receptor binding
and internalization of 68Ga-PSMA-11 in the PC-associated lesions.REFERENCES
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